Zobrazeno 1 - 10
of 100
pro vyhledávání: '"Aidan, Hollis"'
Autor:
Max Alexander Matthey, Aidan Hollis
Publikováno v:
Globalization and Health, Vol 20, Iss 1, Pp 1-8 (2024)
Abstract Background There is an inconsistency in the way pharmaceutical research is financed. While pull mechanisms are predominantly used to incentivize later-stage pharmaceutical research for products with demand in the Global North, so-called negl
Externí odkaz:
https://doaj.org/article/621b83910c684ed5ab07d015f25811bf
Autor:
Sakib Rahman, Aidan Hollis
Publikováno v:
Frontiers in Public Health, Vol 11 (2023)
This paper estimates the effect of antibiotic usage in humans and food-producing animals on the prevalence of resistance in zoonotic bacteria in both humans and animals. Using comprehensive longitudinal data from annual surveillance reports on resist
Externí odkaz:
https://doaj.org/article/3368ec90b83c468aa3851cf5acd2130a
Autor:
Wei Zhang, Huiying Sun, Daphne P. Guh, Larry D. Lynd, Aidan Hollis, Paul Grootendorst, Aslam H. Anis
Publikováno v:
International Journal of Health Policy and Management, Vol 11, Iss 6, Pp 768-776 (2022)
BackgroundGeneric drug prices have been capped at specified percentages of the interchangeable branded drug’s price by the Canadian provincial public drug plans since 1993. The Pan-Canadian Pharmaceutical Alliance, formed as a coalition by the prov
Externí odkaz:
https://doaj.org/article/dd6868a591a248508fa2626b82a10b56
Autor:
Raynell Lang, Jamie L. Benham, Omid Atabati, Aidan Hollis, Trevor Tombe, Blake Shaffer, Katharina Kovacs Burns, Gail MacKean, Tova Léveillé, Brandi McCormack, Hasan Sheikh, Madison M. Fullerton, Theresa Tang, Jean-Christophe Boucher, Cora Constantinescu, Mehdi Mourali, Braden J. Manns, Deborah A. Marshall, Jia Hu, Robert J. Oxoby
Publikováno v:
BMC Public Health, Vol 21, Iss 1, Pp 1-15 (2021)
Abstract Background Public support of public health measures including physical distancing, masking, staying home while sick, avoiding crowded indoor spaces and contact tracing/exposure notification applications remains critical for reducing spread o
Externí odkaz:
https://doaj.org/article/83dd82b8f0ec4b4c9f292e7f0a224dcc
Publikováno v:
Journal of Pharmaceutical Policy and Practice, Vol 14, Iss 1 (2021)
Background Drug repurposing (i.e., finding novel uses for existing drugs) is essential for maximizing medicines’ therapeutic utility, but obtaining regulatory approval for new indications is costly. Policymakers have therefore created temporary ind
Externí odkaz:
https://doaj.org/article/b0d0f34ec1084d27b7dcda3ffadbc9ab
Autor:
Kayley D. McCubbin, R. Michele Anholt, Ellen de Jong, Jennifer A. Ida, Diego B. Nóbrega, John P. Kastelic, John M. Conly, Matthias Götte, Tim A. McAllister, Karin Orsel, Ian Lewis, Leland Jackson, Graham Plastow, Hans-Joachim Wieden, Kathy McCoy, Myles Leslie, Joan L. Robinson, Lorian Hardcastle, Aidan Hollis, Nicholas J. Ashbolt, Sylvia Checkley, Gregory J. Tyrrell, André G. Buret, Elissa Rennert-May, Ellen Goddard, Simon J. G. Otto, Herman W. Barkema
Publikováno v:
Frontiers in Public Health, Vol 9 (2021)
Current limitations in the understanding and control of antimicrobial resistance (AMR) in Canada are described through a comprehensive review focusing on: (1) treatment optimization; (2) surveillance of antimicrobial use and AMR; and (3) prevention o
Externí odkaz:
https://doaj.org/article/af0334612919462f9363cb6a18f8d23f
Autor:
Kavisha Jayasundara, Aidan Hollis, Murray Krahn, Muhammad Mamdani, Jeffrey S. Hoch, Paul Grootendorst
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 14, Iss 1, Pp 1-10 (2019)
Abstract Background High orphan drug prices have gained the attention of payers and policy makers. These prices may reflect the need to recoup the cost of drug development from a small patient pool. However, estimates of the cost of orphan drug devel
Externí odkaz:
https://doaj.org/article/cc6f87a7160342609f8d82d1b195e1db
Publikováno v:
PLoS ONE, Vol 16, Iss 10 (2021)
Background The private versus public contribution to developing new health knowledge and interventions is deeply contentious. Proponents of commercial innovation highlight its role in late-stage clinical trials, regulatory approval, and widespread di
Externí odkaz:
https://doaj.org/article/bbdf4ba2572e407d8c7e6934c1427eef
Publikováno v:
The Journal of Antibiotics. 76:270-278
The use of antibiotics promotes the emergence of resistant bacteria in the patient and the environment. The extent of this well-documented biological relationship is, however, not well characterized at an ecological level. To make good policy around
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5f72b02edfa72da6db4fa2f33645a8b5
https://doi.org/10.1038/s41429-023-00601-6
https://doi.org/10.1038/s41429-023-00601-6
Autor:
Aidan Hollis
Publikováno v:
HealthcarePapers. 21:34-37
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c4e636446afbbea7311e9c33360a8b7d
https://doi.org/10.12927/hcpap.2023.26998
https://doi.org/10.12927/hcpap.2023.26998